PL2943227T3 - Triazynowe radiofarmaceutyki i środki do obrazowania radiologicznego - Google Patents

Triazynowe radiofarmaceutyki i środki do obrazowania radiologicznego

Info

Publication number
PL2943227T3
PL2943227T3 PL14738117T PL14738117T PL2943227T3 PL 2943227 T3 PL2943227 T3 PL 2943227T3 PL 14738117 T PL14738117 T PL 14738117T PL 14738117 T PL14738117 T PL 14738117T PL 2943227 T3 PL2943227 T3 PL 2943227T3
Authority
PL
Poland
Prior art keywords
triazine based
based radiopharmaceuticals
radioimaging agents
radioimaging
agents
Prior art date
Application number
PL14738117T
Other languages
English (en)
Inventor
John W Babich
Craig Zimmerman
John Joyal
Genliang Lu
Original Assignee
Molecular Insight Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Insight Pharmaceuticals, Inc. filed Critical Molecular Insight Pharmaceuticals, Inc.
Publication of PL2943227T3 publication Critical patent/PL2943227T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0497Organic compounds conjugates with a carrier being an organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/48Diagnostic techniques
    • A61B6/481Diagnostic techniques involving the use of contrast agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/50Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Surgery (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dentistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL14738117T 2013-01-14 2014-01-10 Triazynowe radiofarmaceutyki i środki do obrazowania radiologicznego PL2943227T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361752350P 2013-01-14 2013-01-14
US201361785788P 2013-03-14 2013-03-14
EP14738117.2A EP2943227B8 (en) 2013-01-14 2014-01-10 Triazine based radiopharmaceuticals and radioimaging agents
PCT/US2014/011047 WO2014110372A1 (en) 2013-01-14 2014-01-10 Triazine based radiopharmaceuticals and radioimaging agents

Publications (1)

Publication Number Publication Date
PL2943227T3 true PL2943227T3 (pl) 2018-02-28

Family

ID=51167394

Family Applications (2)

Application Number Title Priority Date Filing Date
PL14738117T PL2943227T3 (pl) 2013-01-14 2014-01-10 Triazynowe radiofarmaceutyki i środki do obrazowania radiologicznego
PL17187271T PL3300746T3 (pl) 2013-01-14 2014-01-10 Oparte na triazynie radiofarmaceutyki i środki radioobrazujące

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL17187271T PL3300746T3 (pl) 2013-01-14 2014-01-10 Oparte na triazynie radiofarmaceutyki i środki radioobrazujące

Country Status (14)

Country Link
US (5) US9447121B2 (pl)
EP (4) EP3545978B1 (pl)
JP (2) JP6468602B2 (pl)
KR (1) KR102187940B1 (pl)
CN (1) CN105025933B (pl)
AU (1) AU2014205304B2 (pl)
BR (1) BR112015016585B1 (pl)
CA (1) CA2897437C (pl)
ES (2) ES2738474T3 (pl)
HU (2) HUE035739T2 (pl)
MX (1) MX378439B (pl)
PL (2) PL2943227T3 (pl)
SG (1) SG11201505477TA (pl)
WO (1) WO2014110372A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2897437C (en) * 2013-01-14 2021-12-14 Molecular Insight Pharmaceuticals, Inc. Triazine based radiopharmaceuticals and radioimaging agents
EP3456700A1 (en) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CA2950892C (en) * 2014-05-06 2023-10-24 The Johns Hopkins University Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy
US9956305B2 (en) 2014-09-08 2018-05-01 Molecular Insight Pharmaceuticals, Inc. Organ protection in PSMA-targeted radionuclide therapy of prostate cancer
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
US10688200B2 (en) * 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
RS62274B1 (sr) 2016-03-22 2021-09-30 Univ Johns Hopkins Sredstva sa visokim afinitetom za ciljano dejstvo na membranski antigen specifičan za prostatu za endoradioterapiju kancera prostate
US10340046B2 (en) * 2016-10-27 2019-07-02 Progenics Pharmaceuticals, Inc. Network for medical image analysis, decision support system, and related graphical user interface (GUI) applications
EP3544964B1 (en) 2016-11-28 2020-06-17 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
WO2018222778A1 (en) * 2017-05-30 2018-12-06 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
LT3643707T (lt) * 2017-06-19 2022-05-25 Futurechem Co., Ltd. 18f žymėtas junginys, skirtas prostatos vėžio diagnostikai ir jo panaudojimas
WO2018236115A1 (ko) * 2017-06-19 2018-12-27 (주)퓨쳐켐 전립선암 진단을 위한 18f-표지된 화합물 및 그의 용도
CA3094620C (en) 2018-03-30 2022-11-22 Futurechem Co., Ltd. Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer
IL321215B2 (en) 2018-11-23 2026-05-01 Bayer Ag Contrast media formulation and process for its preparation
JP7729609B2 (ja) * 2019-04-26 2025-08-26 ファイブ イレブン ファーマ インコーポレイテッド 診断および放射性核種治療剤としての前立腺特異的膜抗原(psma)阻害剤
JP2024542539A (ja) * 2021-11-24 2024-11-15 クラリティー・ファーマシューティカルズ・リミテッド がんの処置のための化合物およびその組成物
CN116199736B (zh) * 2023-03-01 2025-03-18 西南医科大学附属医院 一种DOTA-Te-PSMA化合物及其应用

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2730457A (en) 1953-06-30 1956-01-10 Ncr Co Pressure responsive record materials
US2800457A (en) 1953-06-30 1957-07-23 Ncr Co Oil-containing microscopic capsules and method of making them
US2730456A (en) 1953-06-30 1956-01-10 Ncr Co Manifold record material
US3527789A (en) 1967-10-06 1970-09-08 Shell Oil Co Production of poly(lower)alkyl alkenepolycarboxylates
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
JPS5220203B2 (pl) 1973-03-05 1977-06-02
US4272398A (en) 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
JPS6131056A (ja) 1984-07-25 1986-02-13 K Baiorojikaru Sci Lab:Kk ホイッピングクリームの製造方法
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
WO1988001213A1 (en) 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
JP2608550B2 (ja) 1986-10-17 1997-05-07 株式会社 片山化学工業研究所 軟水ボイラの防食処理方法
US4888136A (en) 1988-05-02 1989-12-19 Witco Corporation New flame retardant compositions of matter and cellulosic products containing same
TW353663B (en) 1991-04-06 1999-03-01 Hoechst Ag Process for the preparation of phosphorus-containing L-amino acids, their derivatives and intermediates for this process
JP3051497B2 (ja) 1991-05-17 2000-06-12 株式会社第一ラジオアイソトープ研究所 スルファニルアミド誘導体のテクネチウム錯体をもちいる放射性診断剤
NZ244613A (en) 1991-10-29 1996-05-28 Bracco International B V Subst A ligand containing a hypoxia-localising moiety, preparation thereof; a kit (optionally multivial) for preparing a metal complex containing the ligand
US6359120B1 (en) 1991-10-29 2002-03-19 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia-localizing moiety
IT1270260B (it) 1994-06-21 1997-04-29 Zambon Spa Derivati dell'acido fosfonico ad attivita' inibitrice delle metallopeptidasi
US6011021A (en) 1996-06-17 2000-01-04 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
JP2856098B2 (ja) 1995-04-11 1999-02-10 日本製紙株式会社 感熱記録シート
US5514505A (en) * 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
US5795877A (en) 1996-12-31 1998-08-18 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US5824662A (en) 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
US6046180A (en) 1996-06-17 2000-04-04 Guilford Pharmaceuticals Inc. NAALADase inhibitors
US5672592A (en) 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
US6025344A (en) 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Certain dioic acid derivatives useful as NAALADase inhibitors
US5902817A (en) 1997-04-09 1999-05-11 Guilford Pharmaceuticals Inc. Certain sulfoxide and sulfone derivatives
US6071965A (en) 1996-06-17 2000-06-06 Guilford Pharmaceuticals Inc. Phosphinic alkanoic acid derivatives
US5962521A (en) 1997-04-04 1999-10-05 Guilford Pharmaceuticals Inc. Hydroxamic acid derivatives
PL332413A1 (en) 1996-09-27 1999-09-13 Guilford Pharm Inc Compositions containing inhibitors of naaladase as well as methods of treating glutamatic anomaly and influencing neuronic functions among animals
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
ATE229945T1 (de) 1998-03-19 2003-01-15 Upjohn Co Zur behandlung von cmv infektionen geeignete 1,3, 4-thiadiazole
US6528499B1 (en) 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
US6479470B1 (en) 1999-04-28 2002-11-12 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALAdase
US6228888B1 (en) 1999-07-01 2001-05-08 Guilford Pharmaceuticals Inc. Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors
WO2002094261A1 (fr) 2001-05-24 2002-11-28 Kureha Chemical Industry Company, Limited Medicaments antagonistes de cxcr4 comprenant un compose contenant de l'azote
DE10135355C1 (de) 2001-07-20 2003-04-17 Schering Ag Konjugate makrocyclischer Metallkomplexe mit Biomolekülen und deren Verwendung zur Herstellung von Mitteln für die NMR- und Radiodiagnostik sowie die Radiotherapie
US20030100594A1 (en) 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
WO2003053932A1 (en) 2001-12-21 2003-07-03 Tohru Koike Zinc complexes capable of scavenging substances bearing anionic substituents
ATE443260T1 (de) 2002-01-10 2009-10-15 Univ Johns Hopkins Kontrastmittel und verfahren zum imaging von naaldase oder psma
WO2003077727A2 (en) 2002-03-11 2003-09-25 Biostream, Inc. Technetium-dipyridine complexes, and methods of use thereof
AU2003261974A1 (en) 2002-09-11 2004-04-30 Kureha Chemical Industry Company, Limited Amine compounds and use thereof
US7833734B2 (en) 2002-11-26 2010-11-16 Institute Of Virology Of The Slovak Academy Of Sciences CA IX-specific inhibitors
AU2003295950B2 (en) 2002-11-26 2007-06-28 Institute Of Virology CA IX-specific inhibitors
CA2520259A1 (en) 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
US7682601B2 (en) 2003-04-15 2010-03-23 Mallinckrodt Inc. Bifunctional tridentate pyrazolyl containing ligands for re and tc tricarbonyl complexes
CA2547863A1 (en) 2003-12-12 2005-06-23 Oy Juvantia Pharma Ltd Somatostatin receptor subtype 1 (sstr1) active compounds and their use in therapy
EP1718342A4 (en) 2004-02-12 2009-07-22 Molecular Insight Pharm Inc TECHNETIUM AND RHENIUM-BIS (HETEROARYL) COMPLEXES AND APPLICATION METHODS
GB0421308D0 (en) 2004-09-24 2004-10-27 Amersham Plc Enzyme inhibitor imaging agents
WO2008059489A2 (en) 2006-11-13 2008-05-22 Spectrum Dynamics Llc Radioimaging applications of and novel formulations of teboroxime
WO2006080993A1 (en) 2004-12-08 2006-08-03 Purdue Research Foundation Novel cationic metal complex radiopharmaceuticals
US7741510B2 (en) 2005-01-13 2010-06-22 E. I. Du Pont De Nemours And Company Rheology control agents
US20060155021A1 (en) 2005-01-13 2006-07-13 Lenges Christian P Coating compositions containing rheology control agents
WO2006093991A1 (en) 2005-03-02 2006-09-08 The Cleveland Clinic Foundation Compounds which bind psma and uses thereof
WO2006116736A2 (en) 2005-04-27 2006-11-02 Siemens Medical Solutions Usa, Inc. A method for the preparation of imaging probes using click chemistry
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
FR2890657B1 (fr) 2005-09-15 2007-11-09 Commissariat Energie Atomique Procede d'obtention de complexes de lanthanides hautement luminescents.
CA2625196C (fr) 2005-10-07 2016-04-05 Guerbet Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
EP1961744B1 (en) 2005-11-18 2013-04-17 Ono Pharmaceutical Co., Ltd. Basic group-containing compound and use thereof
BRPI0621307A2 (pt) 2006-02-06 2011-12-06 Ciba Holding Inc. uso de compostos de complexo metálico como catalisadores de oxidação
JP5257068B2 (ja) 2006-05-16 2013-08-07 小野薬品工業株式会社 保護されていてもよい酸性基を含有する化合物およびその用途
ZA200810739B (en) 2006-06-20 2010-03-31 Ishihara Sangyo Kaisha Pesticide containing novel pyridyl-methanamine derivative or its salt
EP2055705A4 (en) 2006-07-31 2014-08-20 Ono Pharmaceutical Co COMPOUND WITH A CYCLIC GROUP BOUND BY A SPIRO BINDING THEREOF AND APPLY THEREOF
JP2010502646A (ja) 2006-08-29 2010-01-28 バイオストリーム セラピューティクス インコーポレーティッド ペプチダーゼ結合部分と結合しペプチダーゼ発現組織及び器官をイメージングする放射性イメージング部分
CA2669127C (en) * 2006-11-08 2016-09-13 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
CA2683434A1 (en) 2007-04-05 2008-10-16 Siemens Medical Solutions Usa, Inc. Development of molecular imaging probes for carbonic anhydrase-ix using click chemistry
WO2009076434A1 (en) 2007-12-12 2009-06-18 Molecular Insight Pharmaceuticals, Inc. Inhibitors of integrin vla-4
US8562945B2 (en) 2008-01-09 2013-10-22 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof
AU2009204133B2 (en) 2008-01-09 2014-04-10 Molecular Insight Pharmaceuticals, Inc. Inhibitors of carbonic anhydrase IX
UY31885A (es) * 2008-06-11 2010-01-29 Astrazeneca Ab Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
EP2349995A1 (en) 2008-09-25 2011-08-03 Molecular Insight Pharmaceuticals, Inc. Selective seprase inhibitors
BRPI0922839A2 (pt) 2008-12-05 2019-09-03 Molecular Insight Pharmaceuticals, Inc. radiofarmacêuticos específicos de ca-ix para tratamento e imageamento de câncer.
WO2010065906A2 (en) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Ca-ix specific radiopharmaceuticals for the treatment and imaging of cancer
EP3495000A1 (en) 2009-02-17 2019-06-12 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
PL3222617T3 (pl) * 2009-03-19 2023-01-02 The Johns Hopkins University Związki do kierunkowania w psma i ich zastosowania
GB201002508D0 (en) * 2010-02-12 2010-03-31 Algeta As Product
WO2012074840A2 (en) * 2010-11-22 2012-06-07 The General Hospital Corporation Compositions and methods for in vivo imaging
US9687572B2 (en) 2010-12-06 2017-06-27 Molecular Insight Pharmaceuticals, Inc. PSMA-targeted dendrimers
PL2739316T3 (pl) * 2011-08-05 2019-09-30 Molecular Insight Pharmaceuticals, Inc. Radioznakowane inhibitory antygenu błonowego specyficznego dla prostaty
US9556167B2 (en) 2012-05-02 2017-01-31 Yale University TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs)
CA2897437C (en) * 2013-01-14 2021-12-14 Molecular Insight Pharmaceuticals, Inc. Triazine based radiopharmaceuticals and radioimaging agents

Also Published As

Publication number Publication date
EP3300746B1 (en) 2019-05-15
CN105025933B (zh) 2019-03-26
HUE035739T2 (en) 2018-05-28
JP2019073532A (ja) 2019-05-16
ES2738474T3 (es) 2020-01-23
EP3545978B1 (en) 2021-09-08
EP2943227A1 (en) 2015-11-18
BR112015016585B1 (pt) 2021-02-02
EP3939972A1 (en) 2022-01-19
CA2897437C (en) 2021-12-14
US10898598B2 (en) 2021-01-26
CA2897437A1 (en) 2014-07-17
US20190134237A1 (en) 2019-05-09
US20210338850A1 (en) 2021-11-04
BR112015016585A2 (pt) 2017-08-22
WO2014110372A1 (en) 2014-07-17
PL3300746T3 (pl) 2019-11-29
EP2943227B1 (en) 2017-09-20
ES2648096T3 (es) 2017-12-28
JP6468602B2 (ja) 2019-02-13
AU2014205304B2 (en) 2018-03-29
MX2015008993A (es) 2016-04-04
MX378439B (es) 2025-03-11
KR102187940B1 (ko) 2020-12-07
US9447121B2 (en) 2016-09-20
US10201624B2 (en) 2019-02-12
EP3545978A1 (en) 2019-10-02
JP2016511231A (ja) 2016-04-14
JP6707677B2 (ja) 2020-06-10
EP2943227B8 (en) 2017-11-22
SG11201505477TA (en) 2015-08-28
HUE044552T2 (hu) 2019-11-28
KR20150115797A (ko) 2015-10-14
AU2014205304A1 (en) 2015-08-13
HK1212908A1 (zh) 2016-06-24
EP3300746A1 (en) 2018-04-04
US20140255306A1 (en) 2014-09-11
US20160346410A1 (en) 2016-12-01
US20170296683A1 (en) 2017-10-19
US10086096B2 (en) 2018-10-02
CN105025933A (zh) 2015-11-04
US11712485B2 (en) 2023-08-01
EP2943227A4 (en) 2016-05-25

Similar Documents

Publication Publication Date Title
SG11201505477TA (en) Triazine based radiopharmaceuticals and radioimaging agents
IL274355B (en) Aza-pyridone compounds and their uses
GB201317286D0 (en) Composition and Use
GB201323008D0 (en) Compounds and uses thereof
IL244434A0 (en) Pyridazinone compounds and their uses
GB201305277D0 (en) Novel combination and use
PL3029038T3 (pl) Związek tetrazolinonowy i jego zastosowanie
GB2513227B (en) Backpack
IL245597A0 (en) Anti-neuroinflammatory and protective compounds in Achillea fragrantissima - implications for inflammatory and neurodegenerative diseases
IL243361B (en) Radioactively labeled material
GB201322456D0 (en) Radiotracer compositions and methods
GB201321056D0 (en) Debug circuitry
GB201307233D0 (en) Compounds and uses thereof
GB201311107D0 (en) Bioorthogonal methods and compounds
EP2974713A4 (en) CERAMIDES FOR FUNCTIONAL ACTIVATION
GB201309180D0 (en) Compounds and Their Uses
ZA201602676B (en) Parent radionuclide container
GB201314936D0 (en) Radiolabelling method
GB201314610D0 (en) Compounds and their uses
GB201306248D0 (en) Compounds and their uses
GB201305297D0 (en) Novel agents and uses thereof
GB201309248D0 (en) Compounds and combinations
AU353456S (en) Hammock
PH32013001091S1 (en) Toothbrush and portions thereof
PH32013001020S1 (en) Toothbrush and portions thereof